DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.